Stanford researchers devised a small, soft skin-like wearable device to monitor health. They are hoping to commercialize their product soon.
Artificial intelligence has delivered a major win for pathologists and researchers in the fight for improved cancer treatments and diagnoses.
A study led by Daniel Spratt, M.D., Vincent K. Smith Chair in Radiation Oncology at University Hospitals Seidman Cancer Center demonstrates the safety and efficacy of a novel oral hormone therapy, relugolix, in conjunction with radiation therapy for treating men with localized and advanced prostate cancer. This work is published in JAMA Oncology.
Only 3% to 5% of people who are diagnosed with this type of brain tumor will be alive three years later. On average, patients live about 14 months after diagnosis.
Now, an experimental therapy that reprograms a person’s own immune cells to attack these tumors is showing some exciting promise.
Three studies published within the past week have reported dramatic results with a therapy called CAR-T delivered directly to the brain. In some cases, tumors have seemingly melted away on brain scans by the next day.
After a decade of investigation, Melbourne researchers have made a discovery that will lead to new ways to treat an aggressive blood cancer ].
A study of more than 21,000 average risk patients at 186 sites across the U.S., led by Regenstrief Institute and Indiana University School of Medicine research scientist Thomas Imperiale, M.D., has found that the next-generation multi-target stool DNA colorectal cancer screening test detects 94% of colorectal cancers. This test has the best performance for detection of both colorectal cancer and advanced precancerous polyps of any noninvasive colorectal cancer screening test.
The study results are published in the New England Journal of Medicine.
“We found that the next-generation stool DNA test had a good balance of sensitivity—detecting disease—and specificity—low false positive results. Compared to the fecal immunochemical test (FIT), the next gen test had superior sensitivity for both colorectal cancer and advanced pre-cancerous polys, especially the subgroup of advanced polyps containing high grade dysplasia,” said Dr. Imperiale, first author of the study.
A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths.
The test looks for DNA fragments shed by tumor cells and precancerous growths. It’s already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year.
In the study, the test caught 83% of the cancers but very few of the precancerous growths found by colonoscopy, the gold standard for colon cancer screening. Besides spotting tumors, colonoscopies can prevent the disease by removing precancerous growths called polyps.
A newly developed “GPS nanoparticle” injected intravenously can home in on cancer cells to deliver a genetic punch to the protein implicated in tumor growth and spread, according to researchers from Penn State. They tested their approach in human cell lines and in mice to effectively knock down a cancer-causing gene, reporting that the technique may potentially offer a more precise and effective treatment for notoriously hard-to-treat basal-like breast cancers.
To combine two low-energy photons into one high-energy photon efficiently, the energy must be able to hop freely, but not too quickly, between randomly oriented molecules of a solid. This Kobe University discovery provides a much-needed design guideline for developing materials for more efficient PV cells, displays, or even anti-cancer therapies.
Light of different colors has different energies and is therefore useful for very different things. For the development of more efficient PV cells, OLED displays, or anti-cancer therapies, it is desirable to be able to upcycle two low-energy photons into a high-energy photon, and many researchers worldwide are working on materials for this up-conversion.
During this process, light is absorbed by the material, and its energy is handed around among the material’s molecules as a so-called “triplet exciton.” However, it was unclear what allows two triplet excitons to efficiently combine their energies into a different excited state of a single molecule that then emits a high-energy photon, and this knowledge gap has been a serious bottleneck in the development of such materials.
Researchers have found a way to stop active cancer cells in their tracks – meaning they can then be eliminated by new drug treatments.
A collaborative research project between the University of Dundee’s Drug Discovery Unit (DDU) and Queen Mary University of London, has identified chemical compounds, called tool molecules, that can halt active cancer cells.
